Abstract:BACKGROUND:Amyloid β (Aβ) accumulates in Alzheimer's disease (AD) brain. Microglial activation also occurs in AD, and this inflammatory response may contribute to disease progression. Microglial activation can be induced by Aβ, but the mechanisms by which this occurs have not been defined. The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) regulates microglial activation in response to several stimuli through its interactions with the transcription factor, NF-κB. The purpose of this study was to evaluate whether PARP-1 activation is involved in Aβ-induced microglial activation, and whether PARP-1 inhibition can modify microglial responses to Aβ.METHODS:hAPP(J20) mice, which accumulate Aβ with ageing, were crossed with PARP-1(-/-) mice to assess the effects of PARP-1 depletion on microglial activation, hippocampal synaptic integrity, and cognitive function. Aβ peptide was also injected into brain of wt and PARP-1(-/-) mice to directly determine the effects of PARP-1 on Aβ-induced microglial activation. The effect of PARP-1 on Aβ-induced microglial cytokine production and neurotoxicity was evaluated in primary microglia cultures and in microglia-neuron co-cultures, utilizing PARP-1(-/-) cells and a PARP-1 inhibitor. NF-κB activation was evaluated in microglia infected with a lentivirus reporter gene.RESULTS:The hAPP(J20) mice developed microglial activation, reduced hippocampal CA1 calbindin expression, and impaired novel object recognition by age 6 months. All of these features were attenuated in hAPP(J20)/PARP-1(-/-) mice. Similarly, Aβ(1-42) injected into mouse brain produced a robust microglial response in wild-type mice, and this was blocked in mice lacking PARP-1 expression or activity. Studies using microglial cultures showed that PARP-1 activity was required for Aβ-induced NF-κB activation, morphological transformation, NO release, TNFα release, and neurotoxicity. Conversely, PARP-1 inhibition increased release of the neurotrophic factors TGFβ and VEGF, and did not impair microglial phagocytosis of Aβ peptide.CONCLUSIONS:These results identify PARP-1 as a requisite and previously unrecognized factor in Aβ-induced microglial activation, and suggest that the effects of PARP-1 are mediated, at least in part, by its interactions with NF-κB. The suppression of Aβ-induced microglial activation and neurotoxicity by PARP-1 inhibition suggests this approach could be useful in AD and other disorders in which microglial neurotoxicity may contribute.

The role of PARP1 in neurodegenerative diseases and aging

[Poly Adenosine Diphosphate-Ribosylation and Neurodegenerative Diseases].

Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases

Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease

PARP1 in the intersection of different DNA repair pathways, memory formation, and sleep pressure in neurons

Decoding the Role of Familial Parkinson’s Disease-Related Genes in DNA Damage and Repair

Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies

PARP1 at the crossroad of cellular senescence and nucleolar processes

Nad(+) Metabolism and Nad(+)-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases

Role of Poly(adp-Ribose) Polymerase-1 in Diabetic Neuropathy

The role of PARP-1 on brain ischemia injury and brain-protection therapy

Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease

Poly(ADP-ribose)polymerase-1 Modulates Microglial Responses to Amyloid Β

Poly(ADP‐ribose) Polymerase 1 (PARP1) in Atherosclerosis: from Molecular Mechanisms to Therapeutic Implications

PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities

Investigation of the mechanism of poly (ADP-ribose) polymerase (PARP) in elderly mouse myocardial ischemia-reperfusion injury

The molecular mechanism of aging and the role in neurodegenerative diseases

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease

PINK1/Parkin-mediated mitophagy in neurodegenerative diseases